Histone Deacetylase Inhibitors Boost Parvovirus Cancer Killing Action
|
By LabMedica International staff writers Posted on 28 Oct 2013 |

Image: Computer-generated representation of parvovirus H-1 (H-1PV) (Photo courtesy of Dr. Antonio Marchini, German Cancer Research Center).
The anticancer action of parvoviruses can be dramatically improved by co-treating cancer cells with parvovirus and histone deacetylase inhibitors (HDACIs) such as valproic acid.
The rat parvovirus H-1PV has oncolytic and tumor-suppressive properties potentially exploitable in cancer therapy. This possibility is being explored by cancer researchers, and while results have been encouraging, they have found that it is necessary to improve the cancer-killing capability of the virus.
Towards this end, investigators at the German Cancer Research Center (Heidelberg) have sought drugs or drug combinations that would improve the ability of parvoviruses to kill cancer cells. In a paper published in the September 17, 2013, online edition of the journal EMBO Molecular Medicine they described the effect of the histone deacetylase inhibitor valproic acid (VPA) on the interaction between H-1PV and human cervical carcinoma and pancreatic carcinoma cell lines.
The investigators showed that co-treatment of cultures with the parvovirus and VPA boosted the ability of the virus to kill a range of human cervical carcinoma and pancreatic carcinoma cell lines by inducing oxidative stress, DNA damage, and apoptosis. Furthermore, in rat and mouse xenograft models, H-1PV/VPA co-treatment strongly inhibited tumor growth promoting complete tumor remission in all co-treated animals. In contrast, animals treated with the same virus dose without the drug displayed no regression, not even when a 20-times higher dose of viruses was administered.
At the molecular level, the investigators found that the parvovirus nonstructural protein NS1 modulated viral transcription and cytotoxicity, both of which were enhanced by VPA treatment. NS1 was acetylated at residues K85 and K257 and addition of VPA correlated with an enhanced rate of NS1 acetylation. In contrast, amino-acid substitution of the two acetylation sites strongly impaired NS1-mediated viral gene transcription, viral replication, and cytotoxicity. VPA induced hyper-acetylation of NS1, which converted the protein into a more active polypeptide.
"The synergistic effect of a combination of parvoviruses and valproic acid enables us to deliver both the viruses and the drug at low doses, which prevents severe side effects," said senior author Dr. Antonio Marchini, a principle investigator in virology at the German Cancer Research Center. "The results are encouraging us to carry out further tests of this combination therapy. We believe it has the potential to arrest tumor growth in severe cases of cancer. We obtained impressive results in preclinical trials with parvovirus H-1 in brain tumors. However, the oncolytic effect of the viruses is weaker in other cancers. Therefore, we are searching for ways to increase the therapeutic potential of the viruses."
Related Links:
German Cancer Research Center
The rat parvovirus H-1PV has oncolytic and tumor-suppressive properties potentially exploitable in cancer therapy. This possibility is being explored by cancer researchers, and while results have been encouraging, they have found that it is necessary to improve the cancer-killing capability of the virus.
Towards this end, investigators at the German Cancer Research Center (Heidelberg) have sought drugs or drug combinations that would improve the ability of parvoviruses to kill cancer cells. In a paper published in the September 17, 2013, online edition of the journal EMBO Molecular Medicine they described the effect of the histone deacetylase inhibitor valproic acid (VPA) on the interaction between H-1PV and human cervical carcinoma and pancreatic carcinoma cell lines.
The investigators showed that co-treatment of cultures with the parvovirus and VPA boosted the ability of the virus to kill a range of human cervical carcinoma and pancreatic carcinoma cell lines by inducing oxidative stress, DNA damage, and apoptosis. Furthermore, in rat and mouse xenograft models, H-1PV/VPA co-treatment strongly inhibited tumor growth promoting complete tumor remission in all co-treated animals. In contrast, animals treated with the same virus dose without the drug displayed no regression, not even when a 20-times higher dose of viruses was administered.
At the molecular level, the investigators found that the parvovirus nonstructural protein NS1 modulated viral transcription and cytotoxicity, both of which were enhanced by VPA treatment. NS1 was acetylated at residues K85 and K257 and addition of VPA correlated with an enhanced rate of NS1 acetylation. In contrast, amino-acid substitution of the two acetylation sites strongly impaired NS1-mediated viral gene transcription, viral replication, and cytotoxicity. VPA induced hyper-acetylation of NS1, which converted the protein into a more active polypeptide.
"The synergistic effect of a combination of parvoviruses and valproic acid enables us to deliver both the viruses and the drug at low doses, which prevents severe side effects," said senior author Dr. Antonio Marchini, a principle investigator in virology at the German Cancer Research Center. "The results are encouraging us to carry out further tests of this combination therapy. We believe it has the potential to arrest tumor growth in severe cases of cancer. We obtained impressive results in preclinical trials with parvovirus H-1 in brain tumors. However, the oncolytic effect of the viruses is weaker in other cancers. Therefore, we are searching for ways to increase the therapeutic potential of the viruses."
Related Links:
German Cancer Research Center
Latest BioResearch News
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
Channels
Clinical Chemistry
view channel
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
Immune checkpoint inhibitors have improved melanoma treatment and extended survival over the past 15 years. However, many patients do not respond, and reliable biomarkers for predicting treatment response... Read more
Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of cases. Acquired ESR1 mutations can cause resistance to endocrine... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







